Navigation Links
Late peak may have prevented severe flu season from becoming worse

The 2004-2005 flu season was at least as severe as the 2003-2004 season, but peaked later according to data from Solucient, a leading provider of healthcare information. This later peak may have prevented the most recent flu season from being even worse.

A flu season's severity is reflected in hospital admissions for community-acquired pneumonia (CAP), one of the most common complications of the flu. Solucient analyzed CAP discharge data from October 2002 through March 2005. The data was provided by ACTrackerTM, an online tool that provides national estimates of hospital and drug utilization approximately 45 days after the end of each month, making the estimates the most timely and current of their kind.

In the 2004-2005 flu season, daily CAP discharges peaked at an average of about 7,000 and 8,000, respectively, in January/February 2005 compared to the previous flu season's December 2003/January 2004 peak. Both these seasons had approximately 31 percent more hospital discharges than the 2002-2003 flu season.

Due to an unusual shortage of flu vaccine, the later peak of the 2004-2005 flu season may have been beneficial, allowing public health officials more time to reallocate and administer the limited supply of vaccine to those most in need -- the elderly and children. This extra time could have been responsible for preventing many more people from becoming ill than would have been expected under the circumstances if the flu peaked at the same time it did the year before.

###

To see a graph showing hospital CAP admissions for 2002-2005, go to http://www.solucient.com/trendtracker


'"/>

Source:Solucient, LLC


Page: 1

Related biology news :

1. Study reveals genomics of inflammation from severe injury
2. Study shows pine bark naturally decreases severe chronic venous insufficiency
3. New treatment for severe malaria
4. Highly concentrated botulinum preparation for cosmetic injections can result in severe illness
5. Hopkins scientists link immune response to ghost parasites and severely congested sinuses
6. New findings could lead to vaccine for severe malaria
7. MRSA toxin acquitted: Study clears suspected key to severe bacterial illness
8. Mutant gene causes severe kidney disease in infants
9. Stanford-led study closes in on genes that may predispose some people to severe depression
10. Amazon rainforest greens up in the dry season
11. Air travel and flu: Post-9/11 restrictions delayed start of season
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Late peak may have prevented severe flu season from becoming worse

(Date:11/4/2014)... 5, 2014 – University of Utah engineers developed the ... jet fuel produce electricity without needing to ignite the ... power portable electronics, off-grid power and sensors. , A ... the American Chemical Society journal ACS Catalysis . ... chemical reaction between a fuel and an oxygen-rich source ...
(Date:11/4/2014)... 2014   3D ... Fuel3D , a developer of 3D scanning ... totaling $6.4 million (£4 million). This funding builds on the ... year and paves the way for the commercial launch of ... funding round was led by Chimera Partners and will be ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... CA Researchers from all over the world will be ... Department of Energy Joint Genome Institute 6th Annual Meeting, ... clean energy generation and the environment. Keynote speeches will ... Linear Accelerator Center, and microbial ecologist Terry Hazen of ...
... March 9, 2011 ActiveRx Rehabilitation , a ... working with senior adults, is now available to franchisees ... active aging. ActiveRx Development Company, Inc., based ... qualified operators interested in single or multi-location opportunities and ...
... - Hybrid plants with multiple genome copies show evidence of ... the genes of the other parent, even to the point ... Brian Dilkes, an assistant professor of genetics at Purdue University, ... California Davis and University of Southern California to study the ...
Cached Biology News:New Healthcare Franchise Opportunity Focuses on Treating Exploding Senior Population 2Study shows how plants sort and eliminate genes over millennia 2
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... patient has been dosed in its Phase 1 ... and cisplatin for the treatment of malignant pleural ...  Polaris Group is conducting clinical trials on ADI-PEG ... other agents, for the treatment of several other ...
(Date:11/18/2014)... -- Cord Blood Registry® (CBR®) announces that the ... Stem Cell Summit, the largest global meeting of stem cell ... Summit will be held December 3-5 at the Marriott Rivercenter ... The World Stem Cell Summit aims to ... convening the most prominent figures in the field to share ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring ... professor in the Regulatory Biology Laboratory at the Salk Institute, ... to an “off switch” for drug resistance in cancer. , ... research is making a global impact in the fight against ... host Cheryl K. Goodman, CEO of Social Global Mobile LLC, ...
(Date:11/18/2014)... 18, 2014 2014 Deep ... is professional and in-depth report on Polytetrahydrofuran ... information, including its definition, characterization, application, and ... This exploration covers the worldwide business investigation, ... examination covering macroeconomic environment & financial circumstance ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... in Cancer Stem Cell Biology Enhances, MacroGenics, Oncology Capabilities ... ... Platforms, ROCKVILLE, Md., July 17 MacroGenics, Inc., a ... and infectious diseases, today announced the,acquisition of Raven Biotechnologies, Inc., ...
... Arno Therapeutics,Inc. (OTC Bulletin Board: ARNI), today announced ... Board has changed from "LRRI.OB" to "ARNI.OB",effective July ... Therapeutics, Inc. is a clinical-stage biopharmaceutical company,that develops ... patients. Arno,s lead compound is AR-67, a novel, ...
... 17 Following intense,speculation in sections of ... Sankyo,Company, Limited (TSE: 4568.JP) ("Daiichi Sankyo") and ... the agreement,between Daiichi Sankyo, Ranbaxy and the ... is binding and final, subject to,regulatory approvals., ...
Cached Biology Technology:MacroGenics Acquires Raven Biotechnologies 2MacroGenics Acquires Raven Biotechnologies 3Arno Therapeutics Announces New Ticker Symbol 2Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation 2
Request Info...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Request Info...
Request Info...
Biology Products: